Short answer
Protagonist Therapeutics, Inc (PTGX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q2 2026 results reported for quarter ended June 30, 2026.
Protagonist Therapeutics, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results reported for quarter ended June 30, 2026
- Corporate update accompanies earnings release in Exhibit 99.1
- Investors should review Exhibit 99.1 for financial metrics and pipeline developments
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation furnished August 5, 2026 under Regulation FD
- Investor-relevant information resides in Exhibit 99.2, potentially covering pipeline and corporate developments
Item EX-99.1 · Exhibit EX-99.2
- Q2 revenue $213.5M, primarily $192.4M Takeda opt-out recognition; reported net income $162.8M versus $34.8M loss
- Cash, equivalents and marketable securities $849.5M, up from $646.0M at December 31, 2025
- Rusfertide NDA under FDA Priority Review with August 2026 PDUFA date; approval could trigger $75M milestone plus royalties up to 29%
- ICOTYDE’s first full commercial quarter supports royalty-based upside, with 6%-10% global sales royalties and up to $580M additional milestones
- R&D expected to increase significantly in second half 2026 as PN-881 advances toward Phase 2 and obesity programs progress
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protagonist Therapeutics, Inc 8-K filings
Get the next PTGX 8-K as it lands
Follow PTGX for push alerts, or ask the research agent what this filing means.